Akciğer kanserinden alınan sürüntü örneğinin patolojik - sitolojik incelenmesinde asbestos parçacıkları ve ayrıca kanser hücreler görülmekte.
Akciğer kanserinin Bilgisayarlı Tomografi görüntüsü
Akciğer kanseri tanısı almış hastada, pnömonektomi ile çıkarılan materyalin çıplak gözle görünümü. Akciğer kanserinin alttipinin ``squamöz hücreli karsinom`` (YASSI EPİTEL HÜCRELİ AKCİĞER KANSERİ) olduğu tespit edilmiş.
AKCİĞER NAKLİ - Son yayınlar
J Heart Lung Transplant. 2009 Aug;28(8):753-8. Epub 2009 Jun 28.
Initial experience with lung donation after cardiocirculatory death in Canada.
Cypel M, Sato M, Yildirim E, Karolak W, Chen F, Yeung J, Boasquevisque C, Leist V, Singer LG, Yasufuku K, Deperrot M, Waddell TK, Keshavjee S, Pierre A.
The Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada.
BACKGROUND: Organ donation after cardiac death (DCD) has the potential to alleviate some of the shortage of suitable lungs for transplantation. Only limited data describe outcomes after DCD lung transplantation. This study describes the early and intermediate outcomes after DCD lung transplantation in Canada. METHODS: Data were collected from donors and recipients involved in DCD lung transplantations between June 2006 and December 2008. Described are the lung DCD protocol, donor characteristics, and the occurrence of post-transplant events including primary graft dysfunction (PGD), bronchial complications, acute rejection (AR), bronchiolitis obliterans syndrome (BOS), and survival. RESULTS: Successful multiorgan controlled DCD increased from 4 donors in 2006 to 26 in 2008. Utilization rates of lungs among DCD donors were 0% in 2006, 11% in 2007, and 27% in 2008. The lung transplant team evaluated 13 DCD donors on site, and lungs from 9 donors were ultimately used for 10 recipients. The 30-day mortality was 0%. Severe PGD requiring extracorporeal membrane oxygenation occurred in 1 patient. Median intensive care unit stay was 3.5 days (range, 2-21 days). Hospital stay was 25 days (range, 9-47 days). AR occurred in 2 patients. No early BOS has developed. Nine (90%) patients are alive at a median of 270 days (range, 47-798 days) with good performance status and lung function. One patient died of sepsis 17 months after transplantation. CONCLUSION: DCD has steadily increased in Canada since 2006. The use of controlled DCD lungs for transplantation is associated with very acceptable early and intermediate clinical outcomes.
PMID: 19632569 [PubMed - indexed for MEDLINE]
Proc Am Thorac Soc. 2009 Jan 15;6(1):66-78.
Surgical techniques: lung transplant and lung volume reduction.
Boasquevisque CH, Yildirim E, Waddel TK, Keshavjee S.
Lung Transplant Program, Department of Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Patients with end-stage emphysema can be offered lung volume reduction surgery (LVRS), lung transplantation, or unilateral lung transplantation combined with contralateral LVRS if necessary, depending on multiple factors including age, lung function parameters, lobar predominance, and whether the disease is uni- or bilateral. Lung transplant is a complex and well-established therapeutic modality for patients with end-stage lung disease. The ideal candidate for LVRS is a patient with severe upper-lobe predominant emphysema and markedly impaired exercise capacity. Other groups may benefit from the procedure, but results are likely to be less good. The objective of this chapter is to describe the surgical techniques of bilateral lung transplantation and lung volume reduction surgery as performed at the University of Toronto.
PMID: 19131532 [PubMed - indexed